Archive | EverLife Capital

Which XPRIZE Healthspan Teams Look Strongest Today?

Aug 26, 2026

The best human evidence, strongest lifespan biology, and most mature drug do not belong to the same team.

Can Any XPRIZE Team Actually Help Us Live Longer?

Aug 25, 2026

The judges are not asking whether one blood marker changes. They want strength, thinking, and immune function to return.

This Company Is Working On Six Problems That Show Up After 45

Aug 17, 2026

Fat gain. Lost muscle. Stiffer tissue. Lower resilience. Heart damage. Inflammation. One private biotech reports a program area related to each.

We Found a Company Trying to Grow Replacement Organ Systems, Not Just One Organ

Aug 7, 2026

Aging rarely damages one organ in isolation. This company is attempting to grow kidneys, livers, hearts, and other organs inside one coordinated developmental system.

The Company Developing More Time for Organ Transplantation

Aug 6, 2026

A review of organ-preservation technology, its public evidence and the milestones that would matter next.

The Company Developing a New Approach to Muscle Regeneration

Aug 5, 2026

One engineered protein. Human testing underway. A company-estimated market exceeding $40 billion.

A New Antimicrobial Platform for Bacteria, Fungi and Enveloped Viruses

Aug 4, 2026

Why a synthetic immune-defense company entered EverLife’s Research Scout list, and the human evidence that must come next

The Companies Studying Thymus Restoration

Jul 29, 2026

The Companies Studying Thymus Restoration

What 55 Mitochondrial Companies Are Trying to Solve

Jul 27, 2026

A few things about your own cells that most people get wrong, what fixing them could mean for your health and lifespan, and how to spot the companies actually worth watching before they hit the headlines.

What Rapamycin Research Has Demonstrated in Humans

Jul 20, 2026

I screened 24 mTOR programs. None clears the full framework today. Three milestones could change the evidence.